Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
amyotrophic lateral sclerosis
Biotech
Verge drops sole clinical candidate in return to AI roots
The decision comes after VRG50635, the company’s lead asset for ALS, failed a pre-specified efficacy analysis in a phase 1 trial.
Darren Incorvaia
Dec 18, 2025 10:04pm
Voyager sets sail on neuro research trek with Transition Bio
Nov 10, 2025 5:23pm
Thermo Fisher debuts protein panel for neurodegeneration R&D
Sep 16, 2025 12:00pm
After delay, Coya receives FDA go-ahead for phase 2 ALS trial
Aug 25, 2025 11:04am
Another biotech hit with FDA delay for ALS asset
Aug 18, 2025 11:01am
Synchron links BCI device to iPad through new Apple protocol
Aug 4, 2025 11:30am
